Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
C4 Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 6,617 shares
@ $1.7, valued at
$11.2k
|
|
| 10/03/2023 |
4
| Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 6,470 shares
@ $1.7, valued at
$11k
|
|
| 10/03/2023 |
4
| GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 8,089 shares
@ $1.7, valued at
$13.8k
|
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/25/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/12/2023 |
4
| REYNO LEONARD (Chief Medical Officer) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 61,300 shares
@ $0
Granted 276,000 options to buy
@ $3.5, valued at
$966k
|
|
| 07/12/2023 |
3
| REYNO LEONARD (Chief Medical Officer) has filed a Form 3 on C4 Therapeutics, Inc. |
| 07/07/2023 |
SC 13G/A
| BlackRock Inc. reports a 4.3% stake in C4 Therapeutics, Inc. |
| 07/05/2023 |
4
| Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 3,976 shares
@ $2.83, valued at
$11.3k
|
|
| 07/05/2023 |
4
| Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 3,887 shares
@ $2.83, valued at
$11k
|
|
| 07/05/2023 |
4
| GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 4,858 shares
@ $2.83, valued at
$13.7k
|
|
| 06/16/2023 |
4
| Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| Bessen Laura (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| DOWNEY BRUCE (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| Koppikar Utpal (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/16/2023 |
4
| Salter Malcolm (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 26,000 options to buy
@ $3.61, valued at
$93.9k
|
|
| 06/12/2023 |
SC 13G/A
| ArrowMark Colorado Holdings LLC reports a 3% stake in C4 Therapeutics, Inc. |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/14/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/04/2023 |
4
| Dubin Glenn (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 3,438 shares
@ $3.2, valued at
$11k
|
|
| 04/04/2023 |
4
| Anderson Kenneth Carl (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 3,516 shares
@ $3.2, valued at
$11.3k
|
|
| 04/04/2023 |
4
| GROGAN DONNA ROY (Director) has filed a Form 4 on C4 Therapeutics, Inc.|
Txns:
| Granted 4,298 shares
@ $3.2, valued at
$13.8k
|
|
| 02/23/2023 |
8-K/A
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/23/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 02/23/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
|
|
|